Geoff Buttfield Posted December 10, 2017 Share Posted December 10, 2017 Researchers halt study early on Bayer’s Xofigo combo study early on safety alert. Back in the spring of 2016, researchers reported that a combination of Bayer’s Xofigo (radium-223) with Zytiga (abiraterone) came through with evidence of significantly reduced bone pain for men suffering from prostate cancer. But scientists were forced to unblind the Phase III pivotal trial prematurely. For further details click on the link below. https://buff.ly/2izbr5f Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.